GIS:FRA
Gilead Sciences, Inc
130,52 €
arrow_upward
+1,78%(+2,28) 1 p
8. okt, 19:52:10 GMT +2 · EUR
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse GIS põhistatistika genereerimine…
Ava
130,86 €
Kõrge
131,76 €
Madal
129,10 €
Turu kapit.
181,90Â mld
Keskm. maht
399,00
Maht
450,00
52 näd kõrgeim
134,58 €
52 näd madalaim
97,05 €
Töötajate arv
17Â tuh
Ava
130,86 €
Kõrge
131,76 €
Madal
129,10 €
Turu kapit.
181,90Â mld
Keskm. maht
399,00
Maht
450,00
52 näd kõrgeim
134,58 €
52 näd madalaim
97,05 €
Töötajate arv
17Â tuh
Uudised
Veebiallikatest ja uudistepartneritelt
AD HOC NEWS
·
23 minuti eest
Gilead Sciences stock costs EUR 130.59, volume 2,080,114 shares
MarketBeat
·
4 tunni eest
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says
GuruFocus
·
1 päeva eest
U.S. Stocks Slip Ahead of Fed Minutes; Gilead Sciences (GILD) Ga
Yahoo Finance
·
1 päeva eest
Gilead Sciences signs five-year DevOps agreement with Cognizant
Profiil
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Teave üksuse Gilead Sciences, Inc kohta
TegevjuhtDaniel O'Day
Töötajad17 tuh
Asutatud22. juuni 1987
PeakontoridFoster City, California, Ameerika Ãœhendriigid
Sektor-
Veebisaitgilead.com